ASSOCIATION OF ANDROGENIC-ANABOLIC STEROID THERAPY WITH DEVELOPMENT OF HEPATOCELLULAR CARCINOMA

F. Leonard Johnson, Kenneth G. Lerner, Marilyn Siegel, John R. Feagler, Philip W. Majerus, John R. Hartmann, E. Donnall Thomas

Research output: Contribution to journalArticle

266 Scopus citations

Abstract

Four patients with aplastic anæmia developed hepatocellular carcinoma after long-term therapy with androgenic-anabolic steroids. In one child there was clinical evidence of tumour regression when the androgen was stopped. There are now epidemiological, clinical, and experimental observations which suggest that an androgenic environment favours development of hepatocellular carcinoma. With the widespread clinical application of androgenic-anabolic steroids (especially their use by athletes) further study to elucidate the precise relationship between this class of drugs and hepatocellular carcinoma is urged.

Original languageEnglish
Pages (from-to)1273-1276
Number of pages4
JournalThe Lancet
Volume300
Issue number7790
DOIs
StatePublished - Dec 16 1972

Fingerprint Dive into the research topics of 'ASSOCIATION OF ANDROGENIC-ANABOLIC STEROID THERAPY WITH DEVELOPMENT OF HEPATOCELLULAR CARCINOMA'. Together they form a unique fingerprint.

  • Cite this

    Johnson, F. L., Lerner, K. G., Siegel, M., Feagler, J. R., Majerus, P. W., Hartmann, J. R., & Thomas, E. D. (1972). ASSOCIATION OF ANDROGENIC-ANABOLIC STEROID THERAPY WITH DEVELOPMENT OF HEPATOCELLULAR CARCINOMA. The Lancet, 300(7790), 1273-1276. https://doi.org/10.1016/S0140-6736(72)92649-9